Logo image of KPRX

KIORA PHARMACEUTICALS INC (KPRX) Stock Fundamental Analysis

NASDAQ:KPRX - US49721T5074 - Common Stock

2.74 USD
-0.06 (-2.14%)
Last: 9/4/2025, 12:54:12 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to KPRX. KPRX was compared to 195 industry peers in the Pharmaceuticals industry. KPRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. KPRX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year KPRX has reported negative net income.
In the past year KPRX has reported a negative cash flow from operations.
KPRX had negative earnings in 4 of the past 5 years.
In the past 5 years KPRX reported 4 times negative operating cash flow.
KPRX Yearly Net Income VS EBIT VS OCF VS FCFKPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M -15M

1.2 Ratios

KPRX has a Return On Assets of -37.51%. This is comparable to the rest of the industry: KPRX outperforms 45.13% of its industry peers.
KPRX has a Return On Equity (-54.15%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -37.51%
ROE -54.15%
ROIC N/A
ROA(3y)-52.66%
ROA(5y)-55.95%
ROE(3y)-106.19%
ROE(5y)-105.72%
ROIC(3y)N/A
ROIC(5y)N/A
KPRX Yearly ROA, ROE, ROICKPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

1.3 Margins

KPRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KPRX Yearly Profit, Operating, Gross MarginsKPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

6

2. Health

2.1 Basic Checks

KPRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, KPRX has more shares outstanding
Compared to 5 years ago, KPRX has more shares outstanding
There is no outstanding debt for KPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KPRX Yearly Shares OutstandingKPRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
KPRX Yearly Total Debt VS Total AssetsKPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

KPRX has an Altman-Z score of -6.00. This is a bad value and indicates that KPRX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of KPRX (-6.00) is worse than 61.54% of its industry peers.
KPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6
ROIC/WACCN/A
WACC10.08%
KPRX Yearly LT Debt VS Equity VS FCFKPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 7.76 indicates that KPRX has no problem at all paying its short term obligations.
With a decent Current ratio value of 7.76, KPRX is doing good in the industry, outperforming 76.41% of the companies in the same industry.
A Quick Ratio of 7.76 indicates that KPRX has no problem at all paying its short term obligations.
KPRX has a better Quick ratio (7.76) than 76.92% of its industry peers.
Industry RankSector Rank
Current Ratio 7.76
Quick Ratio 7.76
KPRX Yearly Current Assets VS Current LiabilitesKPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 68.88% over the past year.
The Revenue for KPRX has decreased by -100.00% in the past year. This is quite bad
KPRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 42.88% yearly.
EPS 1Y (TTM)68.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.89%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y42.88%
Sales Q2Q%-100%

3.2 Future

KPRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.29% yearly.
Based on estimates for the next years, KPRX will show a very strong growth in Revenue. The Revenue will grow by 32.09% on average per year.
EPS Next Y-336.86%
EPS Next 2Y-108.42%
EPS Next 3Y-59.01%
EPS Next 5Y40.29%
Revenue Next Year-91.05%
Revenue Next 2Y-78.85%
Revenue Next 3Y-25.99%
Revenue Next 5Y32.09%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
KPRX Yearly Revenue VS EstimatesKPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2024 2025 2026 2028 2029 2030 2031 2032 100M 200M 300M
KPRX Yearly EPS VS EstimatesKPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2K -4K -6K -8K -10K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KPRX. In the last year negative earnings were reported.
Also next year KPRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KPRX Price Earnings VS Forward Price EarningsKPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KPRX Per share dataKPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

KPRX's earnings are expected to decrease with -59.01% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-108.42%
EPS Next 3Y-59.01%

More info and screens

0

5. Dividend

5.1 Amount

KPRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KIORA PHARMACEUTICALS INC

NASDAQ:KPRX (9/4/2025, 12:54:12 PM)

2.74

-0.06 (-2.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-08 2025-08-08/bmo
Earnings (Next)11-06 2025-11-06
Inst Owners40.51%
Inst Owner Change-27.51%
Ins Owners3.44%
Ins Owner Change16.52%
Market Cap9.40M
Analysts82.5
Price Target11.22 (309.49%)
Short Float %0.72%
Short Ratio0.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.2%
Min EPS beat(2)12.49%
Max EPS beat(2)23.91%
EPS beat(4)2
Avg EPS beat(4)-13.23%
Min EPS beat(4)-85.38%
Max EPS beat(4)23.91%
EPS beat(8)4
Avg EPS beat(8)61.73%
EPS beat(12)7
Avg EPS beat(12)44.89%
EPS beat(16)9
Avg EPS beat(16)23.2%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-28.16%
EPS NQ rev (3m)5.71%
EPS NY rev (1m)-12.59%
EPS NY rev (3m)3.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-33.33%
Revenue NY rev (3m)-33.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.42
P/tB 0.61
EV/EBITDA N/A
EPS(TTM)-2.91
EYN/A
EPS(NY)-2.44
Fwd EYN/A
FCF(TTM)-2.28
FCFYN/A
OCF(TTM)-2.29
OCFYN/A
SpS0
BVpS6.45
TBVpS4.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.51%
ROE -54.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.66%
ROA(5y)-55.95%
ROE(3y)-106.19%
ROE(5y)-105.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 109.4%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.76
Quick Ratio 7.76
Altman-Z -6
F-Score2
WACC10.08%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.89%
EPS Next Y-336.86%
EPS Next 2Y-108.42%
EPS Next 3Y-59.01%
EPS Next 5Y40.29%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y42.88%
Sales Q2Q%-100%
Revenue Next Year-91.05%
Revenue Next 2Y-78.85%
Revenue Next 3Y-25.99%
Revenue Next 5Y32.09%
EBIT growth 1Y-295.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y18.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.91%
OCF growth 3YN/A
OCF growth 5YN/A